Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin.
Ken SatoAtsushi NaganumaTamon NagashimaTakashi HoshinoDaisuke UeharaYousuke AraiKatsuhiko HoriuchiKazuhisa YuasaHisashi TakayamaHirotaka AraiTakeshi HatanakaTatsuya OhyamaHiroki TaharaNaondo SoharaTakeshi KobayashiNorio HoriguchiYuichi YamazakiSatoru KakizakiMotoyasu KusanoMasanobu YamadaTakayo MuraseTakashi NakamuraPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2017)
Elevated serum UA level was a notable AE associated with SOF/RBV therapy for CHG2. However, because of the small number of subjects, the exact frequency of AEs should be re-evaluated with larger cohorts. We need to remember that elevated serum UA level might develop during the therapy, especially at W1.